Acute Promyelocytic Leukemia: A History over 60 Years—From the Most Malignant to the most Curable Form of Acute Leukemia

Thomas, Xavier

doi:10.1007/s40487-018-0091-5

Cited by 54 publications

(63 citation statements)

References 271 publications

(337 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Acute myeloid leukemia (AML) is an aggressive hematological cancer [ 8 , 9 ]. Acute promyelocytic leukemia (APL) is a subset of patients with specific genetic abnormalities and receiving a specific treatment different from other AML patients [ 10 , 11 ]. In the present review, the term AML refers to the non-APL variants of AML.…”

Section: Introductionmentioning

confidence: 99%

The Implementation of Mass Spectrometry-Based Proteomics Workflows in Clinical Routines of Acute Myeloid Leukemia: Applicability and Perspectives

Hernandez-Valladares

Bruserud

Selheim

2020

IJMS

View full text Add to dashboard Cite

With the current reproducibility of proteome preparation workflows along with the speed and sensitivity of the mass spectrometers, the transition of the mass spectrometry (MS)-based proteomics technology from biomarker discovery to clinical implementation is under appraisal in the biomedicine community. Therefore, this technology might be implemented soon to detect well-known biomarkers in cancers and other diseases. Acute myeloid leukemia (AML) is an aggressive heterogeneous malignancy that requires intensive treatment to cure the patient. Leukemia relapse is still a major challenge even for patients who have favorable genetic abnormalities. MS-based proteomics could be of great help to both describe the proteome changes of individual patients and identify biomarkers that might encourage specific treatments or clinical strategies. Herein, we will review the advances and availability of the MS-based proteomics strategies that could already be used in clinical proteomics. However, the heterogeneity of complex diseases as AML requires consensus to recognize AML biomarkers and to establish MS-based workflows that allow their unbiased identification and quantification. Although our literature review appears promising towards the utilization of MS-based proteomics in clinical AML in a near future, major efforts are required to validate AML biomarkers and agree on clinically approved workflows.

show abstract

Section: Introductionmentioning

confidence: 99%

The Implementation of Mass Spectrometry-Based Proteomics Workflows in Clinical Routines of Acute Myeloid Leukemia: Applicability and Perspectives

Hernandez-Valladares

Bruserud

Selheim

2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Since APL was first described in 1957 [10], its management has undergone many changes, evolving from antimetabolite-based therapy to anthracycline and cytarabine-based chemotherapy between 1980 and 1988 [11]. In 1985, ATRA was first used to manage APL.…”

Section: Introductionmentioning

confidence: 99%

“…ATRA demonstrated clinical efficacy when used alone, substantially increasing the incidence of complete remission (CR) but not its durability [12,13]. However, a combination of ATRA with conventional AML chemotherapy was associated with improved outcomes and eradication of APL [11]. In the 1990s, ATO was introduced to treat relapsed APL, which resulted in higher CR rates [14].…”

Section: Introductionmentioning

confidence: 99%

Second Primary Malignancy after Acute Promyelocytic Leukemia: A Population-Based Study

Lenzi

Lee-Jones

Mostofa

et al. 2020

Cancers

View full text Add to dashboard Cite

Acute promyelocytic leukemia (APL), is now highly curable with treatment approaches that include all-trans retinoic acid (ATRA). The high incidence of APL in the Hispanics suggests an association with genetic variants in this population. Information on second primary malignancies (SPMs) in patients with APL is limited. The Surveillance, Epidemiology, and End Results (SEER) database was used to interrogate whether the rate of SPMs in patients with APL was associated with ethnicity and/or ATRA treatment. Between 2000 and 2016, 116 cases of SPM were diagnosed among 4019 patients with APL. The mean age at diagnosis of primary APL was 53.9 years (±15.7 years), and the mean age at diagnosis of SPMs was 59.0 years (±14.5 years). Comparisons with 3774 APL survivors who did not develop SPMs revealed that age ≥40 years at diagnosis of APL (p < 0.001) and non-Hispanic white ethnicity (p = 0.025) were associated with SPMs in APL survivors. Salivary gland, liver, and soft tissue malignancies were significantly more common in patients with primary APL than in individuals with non-APL malignancies. A risk analysis comparing patients who had APL with patients who had non-APL AML suggests that SPMs after APL is associated with ATRA treatment. Therefore, patient follow-up after APL should focus on early diagnosis of SPMs.

show abstract

“…After the pioneering evidence that ATRA is a successful option in the treatment of acute promyelocytic leukemia (APL) [7,8], over the last decades large interest has been attracted in studying the potential use of this retinoid in solid tumors, including pancreatic cancer [9,10]. In cells from pancreatic ductal adenocarcinoma (PDAC), ATRA induces cell-cycle arrest, apoptosis, and epithelial differentiation [11,12] and drives in vitro transdifferentiation into functional insulins secreting cells [13].…”

Section: Introductionmentioning

confidence: 99%

Vav1 Sustains the In Vitro Differentiation of Normal and Tumor Precursors to Insulin Producing Cells Induced by all-Trans Retinoic Acid (ATRA)

Brugnoli

Grassilli

Cardinale

et al. 2020

Stem Cell Rev and Rep

View full text Add to dashboard Cite

All-trans retinoic acid (ATRA) promotes the development and the function of insulin producing cells and induces partial differentiation of pancreatic tumor cells. A number of evidences clearly indicate that the ATRA mediated signaling may have a substantial role in therapeutic approaches based on restoration of functional β-cells. Among the proteins up-regulated by ATRA, Vav1 is involved in maturation and function of haematopoietic cells and is essential for retinoids induced differentiation of tumor promyelocytes. The presence of Vav1 in solid tissues, including pancreas, is considered ectopic and no role in the differentiation of human epithelial cells has so far been described. We demonstrated here that Vav1 sustains the maturation to β-cells of the normal precursors human Biliary Tree Stem/progenitor Cells (hBTSCs) induced by a differentiation medium containing ATRA and that, in the mature normal pancreas, insulin-producing cells express variable levels of Vav1. Using pancreatic ductal adenocarcinoma (PDAC)-derived cells, we also revealed that the ATRA induced up-modulation of Vav1 is essential for the retinoid-induced trans-differentiation of neoplastic cells into insulin producing cells. The results of this study identify Vav1 as crucial molecule in ATRA induced maturation of insulin producing cells and suggest this protein as a marker for new strategies ended to restore functional β-cells.

show abstract

Acute Promyelocytic Leukemia: A History over 60 Years—From the Most Malignant to the most Curable Form of Acute Leukemia

Cited by 54 publications

References 271 publications

The Implementation of Mass Spectrometry-Based Proteomics Workflows in Clinical Routines of Acute Myeloid Leukemia: Applicability and Perspectives

The Implementation of Mass Spectrometry-Based Proteomics Workflows in Clinical Routines of Acute Myeloid Leukemia: Applicability and Perspectives

Second Primary Malignancy after Acute Promyelocytic Leukemia: A Population-Based Study

Vav1 Sustains the In Vitro Differentiation of Normal and Tumor Precursors to Insulin Producing Cells Induced by all-Trans Retinoic Acid (ATRA)

Contact Info

Product

Resources

About